Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide combined with Linperlisib in R/R Follicular Lymphoma
NCT06158386Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Nov 2023
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat and linperlisib in follicular lymphoma (FL), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Complete Response Rate up to 24 months. Started Nov 2023; status: recruiting.
02
Drugs
tucidinostatlinperlisib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT06158386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06158386.